Medical Science
Collaboration Sparks Hope for Next-Generation Obesity Treatments
2025-05-14

A groundbreaking partnership has emerged in the pharmaceutical world, as Novo Nordisk teams up with biotech innovator Septerna to pioneer oral GLP-1 obesity medications. This alliance marks a significant step forward in the race to deliver more user-friendly weight management solutions, positioning them competitively against industry leader Eli Lilly. By focusing on enhancing convenience and effectiveness, this collaboration could redefine how obesity is treated globally.

At the heart of this agreement lies a substantial financial commitment, with Septerna potentially receiving an impressive $2.2 billion from Novo Nordisk. This includes over $200 million in initial and short-term milestone payments, alongside future royalties based on global sales of approved products. Headquartered in the vibrant San Francisco region, Septerna specializes in small molecule drug development, making it an ideal partner for advancing innovative therapies.

The joint venture will initiate four key programs aimed at developing potential treatments targeting G protein-coupled receptors. These include well-known receptors such as GLP-1, GIP, and glucagon hormone receptors. By concentrating on these critical areas, both companies aim to unlock new possibilities in metabolic health, offering hope to millions affected by obesity worldwide. Such advancements underscore the importance of fostering partnerships that drive innovation and improve public health outcomes.

more stories
See more